7NG7

Src kinase bound to eCF506 trapped in inactive conformation

7NG7 の概要

• エントリーDOI: 10.2210/pdb7ng7/pdb
• 分子名称: Proto-oncogene tyrosine-protein kinase Src, 1,2-ETHANEDIOL, tert-butyl (4-(4-amino-1-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)carbamate, ... (4 entities in total)
• 機能のキーワード: src kinase, inhibitor complex, inactive kinase, signaling protein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 33329.26

構造登録者

Lietha, D.,Unciti-Broceta, A. (登録日: 2021-02-08, 公開日: 2021-09-15, 最終更新日: 2024-01-31)

主引用文献

Temps, C.,Lietha, D.,Webb, E.R.,Li, X.F.,Dawson, J.C.,Muir, M.,Macleod, K.G.,Valero, T.,Munro, A.F.,Contreras-Montoya, R.,Luque-Ortega, J.R.,Fraser, C.,Beetham, H.,Schoenherr, C.,Lopalco, M.,Arends, M.J.,Frame, M.C.,Qian, B.Z.,Brunton, V.G.,Carragher, N.O.,Unciti-Broceta, A.
A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
Cancer Res., 81:5438-5450, 2021

PubMed Abstract: Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and . Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders. SIGNIFICANCE: Small molecule-mediated inhibition of SRC impairing both catalytic and scaffolding functions confers increased anticancer properties and tolerability compared with other SRC/ABL inhibitors.

PubMed: 34417202
DOI: 10.1158/0008-5472.CAN-21-0613

実験手法

X-RAY DIFFRACTION (1.5 Å)